Chronic renal failure treated with homocysteine pathogenesis.docVIP

 PAGE \* MERGEFORMAT 22 Chronic renal failure treated with homocysteine pathogenesis [Abstract] homocysteine (Hcy) hyperlipidemia has become a high incidence of cardiovascular disease, independent risk factor for One in chronic renal failure (CRF) patients with high incidence. Hcy by endothelial toxin in stimulating the blood Tube, cardiac smooth muscle cell proliferation, calcium overload in myocardial cells, thrombosis, interference with glutathione synthesis, affect the Transfer reactions in vivo methylation triggered cardiovascular events. Added high-dose folic acid, B vitamins, using the full high - Effective dialysis and renal transplantation is the treatment of CRF patients with hyperlipidemia with Hcy of effective measures. In patients with chronic renal failure, cardiovascular disease (CVD) incidence of 10-20 times higher than the general population , Is a common complication, and one of the leading causes of death [1]. End-stage renal failure (ESRD) patients because of high incidence of CVD in just Some of the traditional risk factors such as: high blood pressure, anemia, diabetes, hypercholesterolemia, smoking, secondary A Hyperthyroidism and other next-shaped gland is difficult to fully explain, has been found that there are still some non-traditional risk factors, such as high Homocysteine (Hcy) hyperlipidemia, etc. [2]. CRF in patients with high Hcy hyperlipidemia prevalence and its incidence is normal 33-fold [3], plasma Hcy for each additional 1μ mol / L, the risk of vascular access thrombosis increased by 4.0% [4], cardiovascular Events (CVE) has increased the risk of 6% [5]. High Hcy has been widely regarded as hyperlipidemia caused by atherosclerosis Increased independent risk factor for CVE [1-13]. 1. Homocysteine metabolism 1.1 in a form Hcy is also called homocysteine, a sulfur-containing amino acids, the composition of the protein does not belong to the 20 kinds of amino acids The body can not synthesis, can only be d